EOLSMEDIUM SIGNALFINANCIAL10-K

EOLS expanded its product portfolio with new Evolysse offerings while experiencing meaningful growth in interest expense alongside modest revenue gains and declining cash reserves.

The company appears to be in a growth investment phase, expanding beyond its core Jeuveau product to include multiple Evolysse variants (Form and Smooth face products), which suggests diversification efforts in the aesthetic medicine market. However, the substantial increase in interest expense coupled with higher debt levels and declining cash position indicates increased financial leverage that warrants monitoring for sustainability.

Comparing 2026-03-03 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

EOLS delivered solid operational growth with revenue advancing 11.6% to $297.2M and proportional increases in SG&A expenses, while R&D spending grew modestly to support product development. The balance sheet shows signs of increased financial strain, with cash declining 38% to $53.8M, total debt rising 20% to $146.1M, and interest expense growing substantially to $13.8M. The combination of lower cash reserves and higher debt service costs suggests the company is funding growth through leverage, creating a more constrained financial profile that requires careful capital allocation going forward.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+52.1%
$9.1M→$13.8M

Interest expense surged 52.1% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
-38.1%
$87.0M→$53.8M

Cash declined 38.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
+20.2%
$121.5M→$146.1M

Debt rose 20.2% — additional borrowing for investment or operations; monitor coverage ratios.

R&D Expense
P&L
+19.9%
$1.7M→$2.1M

R&D investment increased 19.9% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
+19.6%
$63.0M→$75.3M

Current liabilities rose 19.6% — increased short-term obligations, watch current ratio.

Accounts Receivable
Balance Sheet
+14.7%
$47.7M→$54.7M

Receivables grew 14.7% — monitor days sales outstanding for collection efficiency.

Revenue
P&L
+11.6%
$266.3M→$297.2M

Revenue growing 11.6% — solid top-line momentum, watch margins for quality of growth.

SG&A Expense
P&L
+11.5%
$198.0M→$220.8M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-04
ADDED
As of February 27, 2026, 65,059,990 shares of the registrant s sole class of common stock were outstanding.
Securities and Exchange Commission ( SEC ) in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose.
Summary of Risk Factors An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A Risk Factors, in this Annual Report on Form 10-K prior to making an investment in our securities.
As more fully described in Item 1A Risk Factors, the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following: We have incurred significant losses since our inception, and we may continue to incur losses, which could adversely affect the market price of our common stock and our ability to raise additional capital.
Jeuveau , Evolysse Form and Evolysse Smooth face, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from maintaining our market share and expansion.
Our products rely on consumer discretionary spending and the purchasing decisions of our customers, both of which are sensitive to global economic conditions, including the imposition of tariffs, or changes in consumer or customer sentiment.
( Symatese ) to achieve and maintain regulatory approval for the Evolysse product line in the United States.
Failure to obtain approval, maintain approval, or obtain approval on our estimated time frame for additional Evolysse products would negatively affect our ability to sell these products.
If we or our counterparties do not comply with the terms of our settlement agreements (the Medytox Settlement Agreements ) with Medytox, Inc.
( Medytox ), we may face litigation or lose our ability to market and sell Jeuveau , which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern.
REMOVED
As of February 28, 2025, 63,586,753 shares of the registrant s sole class of common stock were outstanding.
Securities and Exchange Commission, or SEC, in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose.
As more fully described in Item 1A Risk Factors , the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following: We have incurred significant losses since our inception.
Jeuveau faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from maintaining our market share and expansion.
We are dependent on Symatese Aesthetics, S.A.S., or Symatese, to achieve regulatory approval for the Evolysse hyaluronic acid gels product line in the United States and Europe.
Failure to obtain approval or obtain approval on our estimated time frame for the Evolysse product line would negatively affect our ability to sell these products.
Ltd, or Daewoong, and Symatese and any termination or loss of significant rights, including exclusivity, under these agreements would materially and adversely affect our business.
We may need to increase the size of our organization, including our sales and marketing capabilities in order to further market and sell Jeuveau and we may experience difficulties in managing this growth.
Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K may appear without the and symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names.
Overview We are a global performance beauty company with a customer-centric approach to delivering breakthrough products.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →